Clinical Trials
9 trialsNCT02842827 2023-07-11
IMG-7289-CTP-101
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 1/2 Completed
NCT00866918 2022-10-25
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT02273102 2020-07-21
TCP-ATRA
University of Miami
Phase 1 Completed
NCT00006239 2017-09-29
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00892190 2016-02-10
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
University of Pittsburgh
Phase 1 Completed
NCT00005863 2013-12-19
Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00005823 2013-12-18
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 3 Completed
NCT00326170 2012-06-15
Phase II 5-Azacytidine Plus VPA Plus ATRA
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00136461 2011-03-10
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Dana-Farber Cancer Institute
Phase 2 Completed